biotech
biotech Articles
aTyr Pharma shares dropped early on Tuesday after the company announced clinical results from its exploratory trials assessing the safety and potential activity of Resolaris.
Published:
Last Updated:
SCYNEXIS shares remained relatively flat on Tuesday after the company provided a clinical update for its antifungal agent.
Published:
Last Updated:
Opthotech Corp. (NASDAQ: OPHT) saw its shares crater on Monday after the company reported late-stage results for its treatment of wet age-related macular degeneration (AMD). The company announced...
Published:
Last Updated:
Alexion Pharmaceuticals saw its shares slide on Monday after the company reported a change in its executive team.
Published:
Last Updated:
Achaogen shares saw a huge gain on Monday after the company reported positive results from a late-stage trial of its lead product candidate.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest was mixed in the selected biotech stocks.
Published:
Last Updated:
A series of new Jefferies reports focus on four biotech stocks that have big upside potential, regardless of the political chatter.
Published:
Last Updated:
Clearside Biomedical now expects to price its 4 million shares at $9.00 per share for a secondary offering valued up to more than $41 million.
Published:
Last Updated:
Shares of Endo International saw a handy gain on Thursday after the company announced that it sold back its rights to an opoid pain drug to BioDelivery Sciences International.
Published:
Last Updated:
Clearside Biomedical expects to price nearly 5 million shares at $15.18 per share in a secondary offering valued up to more than $86 million.
Published:
Last Updated:
Trump told Time that he wants to lower drug prices, a move that has hit the drug and biotech segments due to his comments.
Published:
Last Updated:
Repros Therapeutics saw its shares take a loss on Wednesday after the company provided a key FDA update.
Published:
Last Updated:
TiGenix has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.
Published:
Last Updated:
NeuroDerm has announced that it intends to pursue a comparative bioavailability regulatory path for the its lead product candidate ND0612 based on comparative pharmacokinetic data in place of data...
Published:
Last Updated: